• Publications
  • Influence
Secukinumab in plaque psoriasis--results of two phase 3 trials.
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients withExpand
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
BACKGROUND Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptomsExpand
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
BACKGROUND Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. METHODS In two phase 3 studiesExpand
Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
BACKGROUND An effective prophylactic vaccine would help control the spread of genital herpes. METHODS We conducted two double-blind, randomized trials of a herpes simplex virus type 2 (HSV-2)Expand
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy.
Kaposi's sarcoma (KS) is a mesenchymal tumour involving blood and lymphatic vessels. Only recently has the pathogenesis of this extraordinary neoplasm been elucidated. Viral oncogenesis andExpand
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
BACKGROUND Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis. Previous researchExpand
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
BACKGROUND Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis. OBJECTIVE We sought toExpand
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
Background  In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated.
The interferons. Mechanisms of action and clinical applications.
The interferons (IFN) are one of the body's natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteinsExpand
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.
The pathogenesis of Kaposi's sarcoma (KS) is better understood since the identification of the novel human herpesvirus 8 (HHV8), which can be found in all forms of KS. Viral oncogenesis andExpand